Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

Early trial results of heart drug suggests Novartis has a winner on its hands

1/04/2014 by

W1siziisijiwmtqvmtavmjgvmtuvndyvndavmtc0l2zpbguixsxbinailcj0ahvtyiisijywmhg0mdbcdtawm2uixv0


Novartis has started the week on a high note, with the pharmaceutical company announcing its plans to terminate a drug trial ahead of schedule. The decision was made on the unanimous recommendation of an independent committee, with the company now seeking approval on the basis of the drug’s positive results thus far.

The drug, LCZ696, was recommended after early results showed that patients trialling it lived longer – and without hospitalization – than patients taking enalapril. Designed to treat heart failure, Novartis is going to present the findings and the case for approval at an upcoming meeting with various global health authorities. Milton Packer, co-Principal investigator of trial, confirmed that the evidence in LCZ696′s favor was indeed strong enough to warrant stopping the trial. “The stopping rule was not on the primary endpoint, it was on cardiovascular death,” he said to Forbes’ Larry Husten. “It was a stopping rule that required a very high level of statistical significance for early termination.”

The news comes in contrast to last week’s response to Serelaxin, another Novartis drug that the U.S. Food and Drug Administration (FDA) turned down for approval. Also intended to treat heart disease, Serelaxin did not present a strong enough case, with minimal evidence to support its claims. Earlier this year, a European advisory committee cast similar judgement, limiting Serelaxin’s future in cardiac medicine.

This article has been extracted from http://www.techtimes.com, please click on this link to read the article in full http://www.techtimes.com/articles/5031/20140331/early-trial-results-of-heart-drug-suggests-novartis-has-a-winner-on-its-hands.htm

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

For more information please visit www.montash.com

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtyvmtivmdyvmdkvmjcvmtavnze4l2nsb3vkihrly2hub2xvz3kgc2vydmljzxmuanbnil0swyjwiiwidgh1bwiilcizodb4mtawiyjdxq

AI continues to infiltrate cloud computing se...

2016-12-06 09:00:00 +0000

With Google and Microsoft both already working on artificial intelligence (AI) software for their cloud services, it has been revealed that Amazon is now to join the battle. The internet giant is to prioritise developing AI for Amazon Web Services (AWS), the division that sells data storage and computing to IT professionals around the world. AWS is currently the fastest-growing division for Amazon, with the past year having seen sales soar by 60 per cen...

W1siziisijiwmtyvmtivmduvmtqvmdavmjivmzm1l0jpzybeyxrhlmpwzyjdlfsiccisinrodw1iiiwimzgwedewmcmixv0

Big data analytics – governed data discovery ...

2016-12-05 13:00:00 +0000

Big data analytics has matured as a business process during 2016 with most enterprises now recognising the critical importance of actively mining big data for insights. These insights will inform decision-making and ensure they remain competitive in an increasingly complex landscape that is constantly in flux. One prediction that will certainly come to fruition in the coming years is “more data”. The world’s storage systems are set to hold more than 17....